Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

British Journal of Cancer

Volumn 106, Issue 11, 2012, Pages 1728-1734

  Kaye, S ^a   Aamdal, S ^b   Jones, R ^c   Freyer, G ^d   Pujade Lauraine, E ^e   De Vries, E G E ^f   Barriuso, J ^a   Sandhu, S ^a   Tan, D S W ^a   Hartog, V ^g   Kuenen, B ^g   Ruijter, R ^g   Kristensen, G B ^b   Nyakas, M ^b   Barrett, S ^c   Burke, W ^h   Pietersma, D ^h   Stuart, M ^h   Emeribe, U ^h   Boven, E ^g  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ASTRAZENECA   (United Kingdom)

Author keywords

carboplatin; combination chemotherapy; paclitaxel; saracatinib; Src

Indexed keywords

CARBOPLATIN; PACLITAXEL; SARACATINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; APPETITE; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; COLITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPOKALEMIA; HYPONATREMIA; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEPSIS; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIOXOLES; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; QUINAZOLINES;

EID: 84861458012     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.158     Document Type: Article

References (26)

1. Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J (2010) Phase I safety, pharmacokinetics, and inhibition of Src activity study of saracatinib in patients with solid tumors Clin Cancer Res 16: 4876-4883
2. Boudny V, Nakano S (2002) Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2 Br J Cancer 86: 463-469 (Pubitemid 34185134)
3. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615
4. Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM (2009) Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 15: 3396-3405
5. Cresteil T, Monsarrat B, Alvinerie P, Tréluyer JM, Vieira I, Wright M (1994) Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54: 386-392 (Pubitemid 24053174)
6. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25: 517-525 (Pubitemid 350002958)
7. Elferink F, Van der Vijgh W, Klein I, Vermorken J, Gall H, Pinedo H (1987) Pharmacokinetics of carboplatin after iv administration. Cancer Treat Rep 71: 1231-1237
8. Gevaert O, De Smet F, Van Gorp T, Pochet N, Engelen K, Amant F, De Moor B, Timmerman D, Vergote I (2008) Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation. BMC Cancer 8: 18
9. Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, Elvin P, Boyer B, Carragher N, Plé PA, Bermingham A, Holdgate GA, Ward WH, Hennequin LF, Davies BR, Costello GF (2009) Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 3: 248-261
10. Halder J, Landen CN, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK (2005) Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 11: 8829-8836 (Pubitemid 43005935)
11. Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK (2006) Antiangiogenic and antitumor effects of Src inhibition in ovarian carcinoma. Cancer Res 66: 8633-8639 (Pubitemid 44449178)
12. Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D (2009) ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol Cancer Res 7: 592-600
13. Jamis-Dow CA, Pearl ML, Watkins PB, Blake DS, Klecker RW, Collins JM (1997) Predicting drug interactions in vivo from experiments in vitro: human studies with paclitaxel and ketoconazole. Am J Clin Oncol 20: 592-599 (Pubitemid 27509886)
14. Konecny G, Glas R, Dering J, Manivong K, Qi J, Finn R, Yang G, Hong K, Ginther C, Winterhoff B (2009) Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer 101: 1699-1708
15. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su X, Yang WT, Treekitkarnmongkol W, Andreeff M (2009) Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 15: 1326-1334
16. Masumoto N, Nakano S, Fujishima H, Kohno K, Niho Y (1999) v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Int J Cancer 80: 731-737 (Pubitemid 29066286)
17. Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC (2003) Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 309: 377-383 (Pubitemid 37025902)
18. Peterson-Roth E, Brdlik CM, Glazer PM (2009) Src-induced cisplatin resistance mediated by cell-to-cell communication. Cancer Res 69: 3619-3624
19. Poole C, Lisyanskaya A, Rodenhuis S, Kristensen G, Pujade-Lauraine E, Cantarini M, Emeribe U, Stuart M, Ray-Coquard I (2010) A randomized phase II clinical trial of the Src inhibitor saracatinib (AZD0530) and carboplatin + paclitaxel (C + P) versus C + P in patients (pts) with advanced platinum-sensitive epithelial ovarian cancer (EOC). Ann Oncol 21(Suppl 8): viii304 (abstract 972O)
20. Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, De Bono J, Soria JC, Kaye S, Paoletti X (2011) Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol 29: 1728-1735
21. Talamonti MS, Roh MS, Curley SA, Gallick G (1993) Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91: 53-60 (Pubitemid 23037252)
22. Teoh D, Ayeni TA, Rubatt JM, Adams DJ, Grace L, Starr MD, Barry WT, Berchuck A, Murphy SK, Secord AA (2011) Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. Gynecol Oncol 121: 187-192
23. Van Schaeybroeck S, Kelly DM, Kyula J, Stokesberry S, Fennell DA, Johnston PG, Longley DB (2008) Src and ADAM-17-mediated shedding of transforming growth factor-a is a mechanism of acute resistance to TRAIL. Cancer Res 68: 8312-8321
24. Wheeler DL, Iida M, Dunn EF (2009) The role of Src in solid tumors. Oncologist 14: 667-678
25. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC (2003) Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers 1. Gynecol Oncol 88: 73-79 (Pubitemid 36062670)
26. Zou D, Yoon HS, Anjomshoaa A, Perez D, Fukuzawa R, Guilford P, Humar B (2009) Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Res 11: R45